The Role Clay Siegall is Playing in Transforming the World of Cancer Treatment

Everyone in the medical world agrees that cancer is one of the diseases that have been a menace in the past few decades. The fact that the therapies which have been developed to manage the cases of cancer are only effective when the tumors haven’t spread for long makes treatment a tricky business. However, there are a few researchers who have been trying their best to transform the manner in which cancer treatment is done; and Clay Siegall is one of them. Clay is the co-founder, president, and CEO of Seattle Genetics.

Clay Siegall founded Seattle Genetics in 1998. When he started the company, his dream was to get a cancer treatment or therapies that could work in suppressing cancerous growths, without a lot of side effects. When he started the laboratory, he had very limited resources. The company got their breakthrough when the FDA approved one of the drugs they had been working on ADCETRIS, for the treatment of cancer. For the past six years, the company has been trading on NASDAQ under the name of SGEN.

The company is now looking forward towards getting some other drugs that they have been working on approved by the FDA. They plan to employ more technicians and expand their laboratories to expedite their research. Their pioneer drug, ADCETRIS is currently on sale in more than 66 countries and has placed the company on the global map for the creation of useful therapies for multiple lymphomas. Under the leadership of Clay Siegall, Seattle Genetics has raised more than $1.2billion, both in public and private fundraising. He admits that without this financial support, the company might not have achieved the success that they are enjoying now.

When he was asked whether he is thinking about selling the company to the big Pharma like most of the other clinical trial companies do after striking it big, Clay stated that Seattle Genetics is here to stay. He added that they pulled through it when things were so tight that they didn’t even have enough money to pay their employees, and they are in no way planning to give the company up now.